Open Access Study protocol

Rationale and methods of the cardiometabolic valencian study (escarval-risk) for validation of risk scales in mediterranean patients with hypertension, diabetes or dyslipidemia

Vicente Gil-Guillen1, Domingo Orozco-Beltran14*, Josep Redon2, Salvador Pita-Fernandez3, Jorge Navarro-Pérez2, Vicente Pallares1, Francisco Valls5, Carlos Fluixa6, Antonio Fernandez7, Jose M Martin-Moreno8, Manuel Pascual-de-la-Torre9, Jose L Trillo9, Ramon Durazo-Arvizu10, Richard Cooper10, Marta Hermenegildo9 and Luis Rosado9

Author Affiliations

1 University Miguel Hernandez. Department of Clinical Medicine. San Juan de Alicante, Spain

2 University of Valencia. Department of Medicine. Valencia, Spain

3 University A Coruña. A Coruña, Spain

4 Unión de Mutuas. Castellón, Spain

5 Centro de Salud Beniganim. Valencia, Spain

6 Centro de Salud Benimaclet. Valencia, Spain

7 ESCARVAL Project. Valencia, Spain

8 Director of Programme Management WHO Regional Office for Europe. Copenhagen, Denmark

9 Department of Health; Valencia Government. Valencia, Spain

10 Loyola University of Chicago. Stricht School of Medicine. Department of Preventive Medicine and Epidemiology. Chicago, USA

For all author emails, please log on.

BMC Public Health 2010, 10:717  doi:10.1186/1471-2458-10-717

Published: 22 November 2010

Abstract

Background

The Escarval-Risk study aims to validate cardiovascular risk scales in patients with hypertension, diabetes or dyslipidemia living in the Valencia Community, a European Mediterranean region, based on data from an electronic health recording system comparing predicted events with observed during 5 years follow-up study.

Methods/Design

A cohort prospective 5 years follow-up study has been designed including 25000 patients with hypertension, diabetes and/or dyslipidemia attended in usual clinical practice. All information is registered in a unique electronic health recording system (ABUCASIS) that is the usual way to register clinical practice in the Valencian Health System (primary and secondary care). The system covers about 95% of population (near 5 million people). The system is linked with database of mortality register, hospital withdrawals, prescriptions and assurance databases in which each individual have a unique identification number. Diagnoses in clinical practice are always registered based on IDC-9. Occurrence of CV disease was the main outcomes of interest. Risk survival analysis methods will be applied to estimate the cumulative incidence of developing CV events over time.

Discussion

The Escarval-Risk study will provide information to validate different cardiovascular risk scales in patients with hypertension, diabetes or dyslipidemia from a low risk Mediterranean Region, the Valencia Community.